A comprehensive view of Illnesses/Symptoms/Conditions. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.
Recent Articles
sample of recent headlines, press releases and get more..
Fitch: Covid-19 vaccine sales saw strong start to 2022, with Pfizer and Moderna posting stronger-than-expected Q1 sales; 2022 sales could be comparable to significant 2021 numbers, but estimates for 2023 should see more pronounced decrease in market size
Published:
June 23, 2022
by Fitch Solutions Sector Intelligence
|
Bill Gates sees 50% chance of new pandemic in next 20 years, says mortality rate raised to 5% could be 'end of society' versus COVID's 0.2% mortality rate; solution to prevent next pandemic would cost US$1B/year, compared to US$14B lost to pandemic so far
Published:
June 09, 2022
by CE Noticias Financieras
|
Cantor Fitzgerald expects sales of COVID vaccines and therapeutics to plateau on slowing demand, adequate supplies in many nations; meanwhile, people have opted for boosters at lower rate than they received initial vaccine regimens, further hurting demand
Published:
June 07, 2022
by Indian Health Care News
|
Tech vs. Trees: 3D-printed wooden beehives aim to support bee populations, UK studio reimagines COVID-19 rapid test as paper-based and biodegradable, student spending on print textbooks down as much as 69% in last decade
Published:
May 31, 2022
by Industry Intelligence Inc.
|
BofA initiates Novavax with underperform rating, noting firm’s sales projections for COVID vaccine are below consensus given bearish outlook on continued booster use, uncertain benefits as a differentiated option, drop in immunity against new variants
Published:
May 26, 2022
by Indian Health Care News
|
Ask us about our Government & Public Policy market view
Trending Chart
Interactive chart with headline count